Clinical trial
An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination With Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE STUDY)
NCT01445899 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With a Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating the Efficacy and Safety of PF-04523655 Alone and in Combination With Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE STUDY)
- Lead sponsor
- Quark Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 29, 2012
- Completion date
- November 30, 2013
- Enrollment
- 258 (actual)
- Sites
- 51
Conditions
As the registry lists them; a condition with its own page is linked.
choroidal neovascularization, diabetic macular edema, diabetic retinopathy